Pharmacokinetics of rapamycin-eluting stents in miniswine coronary model

Chinese Medical Journal

Volumn 117, Issue 10, 2004, Pages 1459-1463

  Yu, Meng Yue ^a   Gao, Run Lin ^a   Jiang, Ji ^b   Cheng, Shu Jun ^c   Yuang, Jin Qing ^a   Wang, Chun Ning ^a   Zheng, Jin Gang ^a   Meng, Liang ^a   Zi, Zhen Jun ^d  

^a FUWAI HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d Department of Research   (China)

Author keywords

Pharmacokinetics; Rapamycin; Stents

Indexed keywords

CLARITHROMYCIN; RAPAMYCIN;

ANGIOCARDIOGRAPHY; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; FEASIBILITY STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; RESTENOSIS; RIGHT CORONARY ARTERY; SWINE;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY RESTENOSIS; MALE; MASS SPECTROMETRY; SIROLIMUS; STENTS; SWINE; SWINE, MINIATURE; TISSUE DISTRIBUTION;

EID: 8844282579     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Zhang XX, Cui CC, Xu XG, et al. In vivo distribution of c-myc antisense oligodeoxynucleotides local delivered by gelatin-coated platinum-iridium stents in rabbits and its effect on apoptosis. Chin Med J 2004;117:258-263.
2. Kipshidze N, Leon MB, Tsapenko M, et al. Update on sirolimus drug-eluting stents. Curr Pharm Des 2004;10:337-348.
3. Windecker S, Roffi M, Meier B. Sirolimus eluting stent: a new era in interventional cardiology? Curr Pharm Des 2003; 9:1077-1094.
4. Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 2002; 106: 1505-1509.
5. Sehgal SN, Bansbach CC. Rapamycin: in vitro profile of a new immunosuppressive macrolide. Ann N Y Acad Sci 1993; 685:58-67.
6. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999;99:2164-2170.
7. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimentsional intravascular ultrasound study. Circulation 2001;103:192-195.
8. Poon M, Badimon JJ, Fuster V. Overcoming restenosis with sirulimus: from alphabet soup to clinical reality. Lancet 2002;359:619-622.
9. Serruys PW, Regar E, Carter AJ. Rapamycin eluting stent: the onset of a new era in interventional cardiology. Heart 2002;87:305-307.
10. Marks AR. Rapamycin: signaling in vascular smooth muscle. Transplant Proc 2003;35(3 Suppl):s231-s233.
11. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
12. Kornowski R, Hong MK, Tio FO, et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31:224-230.
13. Svensson JO, Brattstrom C, Sawe J. Determination of rapamycin in whole blood by HPLC. Ther Drug Monit 1997; 19:112-116.
14. Di Marco GS, de Andrade MC, Felipe CR, et al. Determination of sirolimus blood concentration using high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit 2003;25:558-564.
15. Holt DW, Lee T, Johnston A. Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection. Clin Ther 2000;22Suppl B:B38-B48.
16. Napoli KL. A practical guide to the analysis of sirolimus using high-performance liquid chromatography with ultraviolet detection. Clin Ther 2000;22Suppl B:B14-B24.
17. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-1193.
18. MacDonald A, Scarola J, Burke JT, et al. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000;22 Suppl B:B101-B121.
19. Zimmerman JJ, Ferron GM, Lim HK, et al. The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin Pharmacol 1999;39:1155-1161.
20. Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997;37:405-415.
21. Tejani A, Alexander S, Ettenger R, et al. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis. Pediatr Transplant 2004;8:151-160.
22. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001;40:573-585.
23. Holt DW, Denny K, Lee TD, et al. Therapeutic monitoring of sirolimus: its contribution to optimal prescription. Transplant Proc 2003;35(3 Suppl):s157-s161.